Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2012; 33(06): 620-629
DOI: 10.1055/s-0032-1326960
DOI: 10.1055/s-0032-1326960
Biomarkers of Inflammation in Asthma: A Clinical Perspective
Further Information
Publication History
Publication Date:
09 October 2012 (online)
Abstract
Asthma is a heterogeneous disease, with wide variability in pathology, natural history, and response to therapy. Historically, treatment of asthma relied almost exclusively on clinical judgment and pulmonary function tests (spirometry or peak flows), despite the limitations of both. Physiological tests are one step removed from what the clinician needs to know, namely, the underlying activity and whether it is amenable to additional or alternative treatment. Within the past decade, categorization of different pathological phenotypes and the treatment-response phenotypes have been used to guide therapy. Additionally, biomarkers (particular induced sputum analysis and exhaled nitric acid) have been tests to assess disease “activity” and predict potential response (or lack of response) to therapy. Currently, the value of biomarkers from exhaled air or airway fluids remains controversial. Clinical utility is dependent on the performance characteristics in relation to specific clinical questions. Financial constraints applied by health providers and funding agencies have limited the use of induced sputum analysis and exhaled nitric oxide to date. However, evaluation of candidate biomarkers has provided important insights in clinical practice and in research settings. At the very least, existing techniques should have a regular place in severe asthma clinics, if not more widely, where heterogeneity is the norm and not all asthma is what it seems.
-
References
- 1 Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368 (9537) 804-813
- 2 Taylor DR, Bateman ED, Boulet LP , et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32 (3) 545-554
- 3 Diamant Z, Boot JD, Mantzouranis E, Flohr R, Sterk PJ, Gerth van Wijk R. Biomarkers in asthma and allergic rhinitis. Pulm Pharmacol Ther 2010; 23 (6) 468-481
- 4 Vijverberg SJ, Koenderman L, Koster ES, van der Ent CK, Raaijmakers JA, Maitland-van der Zee AH. Biomarkers of therapy responsiveness in asthma: pitfalls and promises. Clin Exp Allergy 2011; 41 (5) 615-629
- 5 Maisel A, Mueller C, Adams Jr K , et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10 (9) 824-839
- 6 British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 58 (6) 470-483
- 7 Kowal K, Bodzenta-Lukaszyk A, Zukowski S. Exhaled nitric oxide in evaluation of young adults with chronic cough. J Asthma 2009; 46 (7) 692-698
- 8 Fabbri LM, Romagnoli M, Corbetta L , et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167 (3) 418-424
- 9 Contoli M, Baraldo S, Marku B , et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 2010; 125 (4) 830-837
- 10 Chanez P, Vignola AM, O'Shaugnessy T , et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155 (5) 1529-1534
- 11 Pavord ID, Shaw DE, Gibson PG, Taylor DR. Inflammometry to assess airway diseases. Lancet 2008; 372 (9643) 1017-1019
- 12 Dragonieri S, Schot R, Mertens BJ , et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007; 120 (4) 856-862
- 13 Montuschi P, Santonico M, Mondino C , et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest 2010; 137 (4) 790-796
- 14 Bateman ED, Boushey HA, Bousquet J , et al; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170 (8) 836-844
- 15 Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 1958; 2 (7059) 1245-1247
- 16 Bacci E, Cianchetti S, Bartoli M , et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006; 129 (3) 565-572
- 17 Berry M, Morgan A, Shaw DE , et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62 (12) 1043-1049
- 18 Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57 (10) 875-879
- 19 Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353 (9171) 2213-2214
- 20 Pizzichini E, Pizzichini MM, Gibson P , et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158 (5 Pt 1) 1511-1517
- 21 Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006; 27 (5) 964-971
- 22 Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koëter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32 (7) 1096-1103
- 23 Barnes PJ, Dweik RA, Gelb AF , et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010; 138 (3) 682-692
- 24 Schleich FN, Seidel L, Sele J , et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 2010; 65 (12) 1039-1044
- 25 Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65 (5) 384-390
- 26 Smith AD, Cowan JO, Brassett KP , et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172 (4) 453-459
- 27 Dummer JF, Epton MJ, Cowan JO , et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med 2009; 180 (9) 846-852
- 28 Hahn PY, Morgenthaler TY, Lim KG. Use of exhaled nitric oxide in predicting response to inhaled corticosteroids for chronic cough. Mayo Clin Proc 2007; 82 (11) 1350-1355
- 29 Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65 (5) 384-390
- 30 Haldar P, Pavord ID, Shaw DE , et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178 (3) 218-224
- 31 Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161 (1) 64-72
- 32 Deykin A, Lazarus SC, Fahy JV , et al; Asthma Clinical Research Network, National Heart, Lung, and Blood Institute/NIH. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115 (4) 720-727
- 33 Jayaram L, Pizzichini MM, Cook RJ , et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27 (3) 483-494
- 34 Green RH, Brightling CE, McKenna S , et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360 (9347) 1715-1721
- 35 D'silva L, Gafni A, Thabane L , et al. Cost analysis of monitoring asthma treatment using sputum cell counts. Can Respir J 2008; 15 (7) 370-374
- 36 Petsky HL, Cates CJ, Lasserson TJ , et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67 (3) 199-208
- 37 Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy 2009; 39 (4) 478-490
- 38 Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352 (21) 2163-2173
- 39 Powell H, Murphy VE, Taylor DR , et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind randomised controlled trial. Lancet 2011; 378 (9795) 983-990
- 40 Pérez De Llano LA, Carballada F, Castro Añón O , et al. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010; 35 (6) 1221-1227
- 41 Hashimoto S, Brinke AT, Roldaan AC , et al. Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax 2011; 66 (6) 514-520
- 42 Hewitt RS, Modrich CM, Cowan JO, Herbison GP, Taylor DR. Outcomes using exhaled nitric oxide measurements as an adjunct to primary care asthma management. Prim Care Respir J 2009; 18 (4) 320-327
- 43 Dweik RA, Boggs PB, Erzurum SC , et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184 (5) 602-615
- 44 van Veen IH, Ten Brinke A, Sterk PJ , et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008; 32 (2) 344-349
- 45 Caudri D, Wijga AH, Hoekstra MO , et al. Prediction of asthma in symptomatic preschool children using exhaled nitric oxide, Rint and specific IgE. Thorax 2010; 65 (9) 801-807
- 46 Dweik RA, Sorkness RL, Wenzel S , et al; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181 (10) 1033-1041
- 47 Tossa P, Paris C, Zmirou-Navier D , et al. Increase in exhaled nitric oxide is associated with bronchial hyperresponsiveness among apprentices. Am J Respir Crit Care Med 2010; 182 (6) 738-744
- 48 Prasad A, Langford B, Stradling JR, Ho LP. Exhaled nitric oxide as a screening tool for asthma in school children. Respir Med 2006; 100 (1) 167-173
- 49 Kostikas K, Papaioannou AI, Tanou K, Koutsokera A, Papala M, Gourgoulianis KI. Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest 2008; 133 (4) 906-913
- 50 Arora R, Thornblade CE, Dauby PA, Flanagan JW, Bush AC, Hagan LL. Exhaled nitric oxide levels in military recruits with new onset asthma. Allergy Asthma Proc 2006; 27 (6) 493-498
- 51 Deykin A, Massaro AF, Drazen JM, Israel E. Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. Am J Respir Crit Care Med 2002; 165 (12) 1597-1601
- 52 Malmberg LP, Pelkonen AS, Haahtela T, Turpeinen M. Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma. Thorax 2003; 58 (6) 494-499
- 53 Smith AD, Cowan JO, Filsell S , et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004; 169 (4) 473-478
- 54 Pedrosa M, Cancelliere N, Barranco P, López-Carrasco V, Quirce S. Usefulness of exhaled nitric oxide for diagnosing asthma. J Asthma 2010; 47 (7) 817-821
- 55 Lex C, Dymek S, Heying R, Kovacevic A, Kramm CM, Schuster A. Value of surrogate tests to predict exercise-induced bronchoconstriction in atopic childhood asthma. Pediatr Pulmonol 2007; 42 (3) 225-230
- 56 Baur X, Barbinova L. Latex allergen exposure increases exhaled nitric oxide in symptomatic healthcare workers. Eur Respir J 2005; 25 (2) 309-316
- 57 Ferrazzoni S, Scarpa MC, Guarnieri G, Corradi M, Mutti A, Maestrelli P. Exhaled nitric oxide and breath condensate pH in asthmatic reactions induced by isocyanates. Chest 2009; 136 (1) 155-162
- 58 Vahlkvist S, Sinding M, Skamstrup K, Bisgaard H. Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure. J Allergy Clin Immunol 2006; 117 (6) 1272-1276
- 59 Hewitt RS, Smith AD, Cowan JO, Schofield JC, Herbison GP, Taylor DR. Serial exhaled nitric oxide measurements in the assessment of laboratory animal allergy. J Asthma 2008; 45 (2) 101-107
- 60 Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005; 60 (5) 383-388
- 61 Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000; 55 (3) 232-234
- 62 McNicholl DM, Stevenson M, McGarvey L, Heaney L. Developing and validating a FeNO suppression test identifying non-adherence in difficult asthma. Am J Respir Crit Care Med 2011; 183: A4379
- 63 Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60 (3) 215-218
- 64 Zacharasiewicz A, Wilson N, Lex C , et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005; 171 (10) 1077-1082
- 65 Jones SL, Kittelson J, Cowan JO , et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164 (5) 738-743
- 66 Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006; 129 (6) 1492-1499
- 67 Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008; 31 (3) 539-546
- 68 Michils A, Louis R, Peché R, Baldassarre S, Van Muylem A. Exhaled nitric oxide as a marker of asthma control in smoking patients. Eur Respir J 2009; 33 (6) 1295-1301